1. |
Xue K, Groppe M, Salvetti AP, et al. Technique of retinal gene therapy: delivery of viral vector into the subretinal space[J]. Eye, 2017, 31(9): 1308-1316. DOI: 10.1038/eye.2017.158.
|
2. |
MacLaren RE, Groppe M, Barnard AR, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial[J]. Lancet, 2014, 383(9923): 1129-1137. DOI: 10.1016/S0140-6736(13)62117-0.
|
3. |
Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2017, 390(10097): 849-860. DOI: 10.1016/S0140-6736(17)31868-8.
|
4. |
Cehajic-Kapetanovic J, Xue K, Martinez-Fernandez de la Camara C, et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR[J]. Nat Med, 2020, 26(3): 354-359. DOI: 10.1038/s41591-020-0763-1.
|
5. |
Garafalo AV, Cideciyan AV, Héon E, et al. Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives[J/OL]. Prog Retin Eye Res, 2020, 77: 100827[2019-12-30]. https://pubmed.ncbi.nlm.nih.gov/31899291/. DOI: 10.1016/j.preteyeres.2019.100827.
|
6. |
中华医学会眼科学分会眼底病学组. 中国视网膜下基因治疗药物注射术操作规范推荐专家共识(2022)[J]. 中华实验眼科杂志, 2022, 40(10): 887-893. DOI: 10.3760/cma.j.cn115989-20220808-00366.Fundus Disease Group of Chinese Medical Association Ophthalmology Branch. Expert consensus on surgical technique for subretinal injection of gene therapy in China (2022)[J]. Chin J Exp Ophthalmol, 2022, 40(10): 887-893. DOI: 10.3760/cma.j.cn115989-20220808-00366.
|
7. |
Davis JL, Gregori NZ, MacLaren RE, et al. Surgical technique for subretinal gene therapy in humans with inherited retinal degeneration[J]. Retina, 2019, 39(Suppl 1): S2-8. DOI: 10.1097/IAE.0000000000002609.
|
8. |
Ladha R, Caspers LE, Willermain F, et al. Subretinal therapy: technological solutions to surgical and immunological challenges[J/OL]. Front Med (Lausanne), 2022, 9: 846782[2022-03-23]. https://pubmed.ncbi.nlm.nih.gov/35402424/. DOI: 10.3389/fmed.2022.846782.
|
9. |
孙晓东, 陈洁琼. 重视眼部基因治疗病毒载体相关免疫的监测与处理[J]. 中华眼底病杂志, 2022, 38(8): 621-625. DOI: 10.3760/cma.j.cn511434-20220629-00389.Sun XD, Chen JQ. Pay attention to the detection and treatment of ocular gene therapy viral vector-associated immunity[J]. Chin J Ocul Fundus Dis, 2022, 38(8): 621-625. DOI: 10.3760/cma.j.cn511434-20220629-00389.
|
10. |
梁莉聪, 佘凯芩, 陆方. 视网膜疾病基因治疗递送方式的研究现状与进展[J]. 中华眼底病杂志, 2024, 40(1): 67-75. DOI: 10.3760/cma.j.cn511434-20220803-00435.Liang LC, She KQ, Lu F. The status and progress of gene therapy delivery techniques for retinal diseases[J]. Chin J Ocul Fundus Dis, 2024, 40(1): 67-75. DOI: 10.3760/cma.j.cn511434-20220803-00435.
|
11. |
Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis[J]. N Engl J Med, 2008, 358(21): 2240-2248. DOI: 10.1056/NEJMoa0802315.
|
12. |
Fan KC, Yannuzzi NA, Patel NA, et al. Surgical techniques for the subretinal delivery of pediatric gene therapy[J]. Ophthalmol Retina, 2020, 4(6): 644-645. DOI: 10.1016/j.oret.2020.01.023.
|
13. |
Blodi BA, Paluska SA. Cataract after vitrectomy in young patients[J]. Ophthalmology, 1997, 104(7): 1092-1095. DOI: 10.1016/s0161-6420(97)30180-8.
|
14. |
Nuzbrokh Y, Kassotis AS, Ragi SD, et al. Treatment-emergent adverse events in gene therapy trials for inherited retinal diseases: a narrative review[J]. Ophthalmol Ther, 2020, 9(4): 709-724. DOI: 10.1007/s40123-020-00287-1.
|
15. |
Hernandez-Bogantes E, Abdala-Figuerola A, Olivo-Payne A, et al. Cataract following pars plana vitrectomy: a review[J]. Semin Ophthalmol, 2021, 36(8): 824-831. DOI: 10.1080/08820538.2021.1924799.
|
16. |
Peyman GA, Nelson NC, Alturki W, et al. Tissue plasminogen activating factor assisted removal of subretinal hemorrhage[J]. Ophthalmic Surg, 1991, 22(10): 575-582.
|
17. |
Ducloyer JB, Le Meur G, Lebranchu P, et al. Macular fold complicating a subretinal injection of voretigene neparvovec[J]. Ophthalmology Retina, 2020, 4(4): 456-458. DOI: 10.1016/j.oret.2019.12.005.
|
18. |
刘晶劼, 刘勃实, 李筱荣. 吊顶灯辅助照明技术在巩膜扣带术治疗孔源性视网膜脱离中的应用进展[J]. 眼科新进展, 2023, 43(10): 814-818. DOI: 10.13389/j.cnki.rao.2023.0164.Liu JJ, Liu BS, Li XR. Advances in the application of chandelier illumination system in scleral buck-ling for rhegmatogenous retinal detachment[J]. Rec Adv Ophthalmol, 2023, 43(10): 814-818. DOI: 10.13389/j.cnki.rao.2023.0164.
|
19. |
Cai X, Zhao P, Zhang Q, et al. Treatment of stage 3 Coats’ disease by endolaser photocoagulation via a two-port pars plana nonvitrectomy approach[J]. Graefe's Arch Clin Exp Ophthalmol, 2015, 253(7): 999-1004. DOI: 10.1007/s00417-015-2984-4.
|
20. |
Wood EH, Rao P, Mahmoud TH. Nanovitreoretinal subretinal gateway device to displace submacular hemorrhage: access to the subretinal space without vitrectomy[J]. Retina, 2022, 42(11): 2225-2228. DOI: 10.1097/IAE.0000000000002669.
|
21. |
余晓, 刘腾, 邹玉凌, 等. 视网膜下注射阿柏西普治疗难治性息肉样脉络膜血管病变疗效的初步研究[J]. 中华眼底病杂志, 2024, 40(2): 122-128. DOI: 10.3760/cma.j.cn511434-20231115-00457.Yu X, Liu T, Zou YL, et al. Preliminary study on the efficacy of subretinal injection of Aflibercept in the treatment of refractory polypoidal choroidal vasculopathy[J]. Chin J Ocul Fundus Dis, 2024, 40(2): 122-128. DOI: 10.3760/cma.j.cn511434-20231115-00457.
|